中国卫生标准管理
中國衛生標準管理
중국위생표준관리
CHINA HEALTH STANDARD MANAGEMENT
2015年
8期
234-235
,共2页
冠心病%瑞舒伐他汀%曲美他嗪%疗效%血脂
冠心病%瑞舒伐他汀%麯美他嗪%療效%血脂
관심병%서서벌타정%곡미타진%료효%혈지
Coronary heart disease%Rosuvastatin%Trimetazidine%Efficacy%Lipid
目的：探究对冠心病患者采用曲美他嗪+瑞舒伐他汀联合治疗的效果。方法以120例冠心病患者为研究对象，纳入时间为2012年8月～2014年8月，按照随机数字表法随机分组，观察组60例，给予联合药物治疗（曲美他嗪+瑞舒伐他汀），对照组60例，给予曲美他嗪联合普罗布考治疗，比较两组患者的临床疗效。结果观察组患者的临床疗效为93.3%，对照组为81.7%，观察组明显高于对照组，P<0.05；治疗后观察组患者的血脂水平改善情况优于对照组，两组比较差异具有统计学意义，P<0.05。结论对冠心病患者采用曲美他嗪+瑞舒伐他汀联合治疗效果显著。
目的：探究對冠心病患者採用麯美他嗪+瑞舒伐他汀聯閤治療的效果。方法以120例冠心病患者為研究對象，納入時間為2012年8月～2014年8月，按照隨機數字錶法隨機分組，觀察組60例，給予聯閤藥物治療（麯美他嗪+瑞舒伐他汀），對照組60例，給予麯美他嗪聯閤普囉佈攷治療，比較兩組患者的臨床療效。結果觀察組患者的臨床療效為93.3%，對照組為81.7%，觀察組明顯高于對照組，P<0.05；治療後觀察組患者的血脂水平改善情況優于對照組，兩組比較差異具有統計學意義，P<0.05。結論對冠心病患者採用麯美他嗪+瑞舒伐他汀聯閤治療效果顯著。
목적：탐구대관심병환자채용곡미타진+서서벌타정연합치료적효과。방법이120례관심병환자위연구대상，납입시간위2012년8월～2014년8월，안조수궤수자표법수궤분조，관찰조60례，급여연합약물치료（곡미타진+서서벌타정），대조조60례，급여곡미타진연합보라포고치료，비교량조환자적림상료효。결과관찰조환자적림상료효위93.3%，대조조위81.7%，관찰조명현고우대조조，P<0.05；치료후관찰조환자적혈지수평개선정황우우대조조，량조비교차이구유통계학의의，P<0.05。결론대관심병환자채용곡미타진+서서벌타정연합치료효과현저。
Objective To explore the use of coronary heart disease in patients with trimetazidine rosuvastatin combined therapy.Methods 120 cases of coronary heart disease patients for the study,included in time from August 2012 to August 2014,according to the random number table,randomized, observation group,60 patients received combination therapy(trimetazidine rosuvastatin atorvastatin),a control group of 60 patients received trimetazidine combined probucol therapy,the clinical efficacy of two groups were compared.Results The clinical efficacy in patients was 93.3% in the control group was 81.7%,significantly higher than the observation group,P<0.05; lipid levels in patients with post-treatment observation group to improve the situation better than the control group,the difference was parity statisticaly significant,P<0.05.Conclusion The patients with coronary heart disease trimetazidine rosuvastatin combined treatment effect is significant,worthy of attention and promotion.
